Implant Sciences to Exhibit at the 13th Transport Security Expo in London

Todd Silvestri, Chief Operating Officer, will be speaking on - "The Cost of High ETD False Alarm Rates on Airport Operations"

Nov 30, 2015, 09:00 ET from Implant Sciences Corporation

WILMINGTON, Mass., Nov. 30, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, announced that it will exhibit at the 13th Transport Security Expo (Transec) from December 2-3, 2015 in London, United Kingdom. Implant Sciences will have its QS-B220 Desktop Explosives and Drugs Trace Detector available for demonstrations in booth G-1.

The Transport Security Expo is the global platform, bringing together government, industry and academia to counter the threat against transportation networks around the world.  The Transport Security Expo in its 13th edition with over 4,500 attendees and 200 exhibitors is the vital platform for providers of security solutions to meet critical end-user decision makers with high-value contracts to place.

Implant Sciences' Chief Operating Officer, Todd Silvestri, will be speaking on "The Benefits of ETDs with Low False Alarm Rates". A recent EU mandate, which took effect September 1, 2015 for airports with over 500,000 passengers, requires the screening of 15% of passengers and additional regulations for smaller airports are scheduled to follow. The majority of these airports chose to comply with the regulation with Explosives Trace Detection (ETD) systems. Implant Sciences will demonstrate how EU airports can save money on their security screening operations by utilizing ETD systems with critical performance features, such as a low False Alarm Rate (FAR). 

"Implant Sciences' technology has revolutionized the trace detection industry. Our ETD systems are recognized for having the lowest false alarm rate in the industry and other differentiating features that help make checkpoint screening effective, efficient and speedy. We look forward to demonstrating its importance to airport operators at the event," stated Todd Silvestri, Implant Sciences' Chief Operating Officer. "We are happy to exhibit at Transec and to showcase our thought leadership in this area of expertise."

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 70 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the 2015 GSN Airport/Seaport/Border Security Award for "Best Security Checkpoint".  All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at

Cautionary Note Regarding Forward-Looking Statements

This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements.  Such risks and uncertainties include, but are not limited to, the risks that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; the risk that the Company may not be able to meet demand for its products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K.  In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements.  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.


Implant Sciences Corporation
Company Contact:
Robert Liscouski
978-752-1700 x 116    

SOURCE Implant Sciences Corporation